Alphamab Oncology (FRA:3NK) Dividends per Share: €0.00 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3NK Alphamab Oncology FRA:3NK
55 GF Score
Price €0.88
GF Value €0.82
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Dividends per Share?

Alphamab Oncology FRA:3NK +0.57% 55 Dividends per Share is €0.00 as of Dec. 2025. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review.

Alphamab Oncology's dividends per share for the six months ended in Dec. 2025 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00. As of today, Alphamab Oncology's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Alphamab Oncology  (FRA:3NK) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Alphamab Oncology's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.017
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Dividends per Share Related Terms

Alphamab Oncology Dividends per Share Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Dividends per Share Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:3NK vs VRTX, REGN, RVMD: Dividends per Share Comparison

For the Biotechnology subindustry, Alphamab Oncology's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Dividend Yield % falls into.


FRA:3NK
55GF Score
Alphamab Oncology FRA:3NK
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of €0.00 mean?
Alphamab Oncology (FRA:3NK) has a Dividends per Share of €0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Dividends per Share too high?
Alphamab Oncology's current Dividends per Share is €0.00. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Dividends per Share compare to VRTX and REGN?
Alphamab Oncology's Dividends per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Dividends per Share of €0.00. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Dividends per Share is €0.00. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Dividends per Share is €0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.

Key valuation signals for FRA:3NK:

  • Dividends per Share: €0.00
  • GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for FRA:3NK

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.82
GF Value